Novus Therapeutics – Consensus Indicates Potential 105.9% Upside

Broker Ratings

Novus Therapeutics with ticker code (NVUS) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 43 and 27 with a mean TP of 35. With the stocks previous close at 17 this would imply there is a potential upside of 105.9%. The day 50 moving average is 20.7 and the 200 day moving average is 13.83. The company has a market capitalisation of $24m. Find out more information at:

Novus Therapeutics, a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics is headquartered in Irvine, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index